Connect@: Fall into Networking
Pennsylvania Bio has launching a new series this year called “Connect@” for members to network in a casual and relaxed atmosphere. Thank you to Deloitte for hosting Pennsylvania Bio.
*This event is free for members of Pennsylvania Bio. Space is limited; you must register in advance!
When: October 5, 2016
Where: Center City, Philadelphia
Time: 5:00 - 7:00PM
Schedule:
5:00 p.m. – Start
5:45 p.m. – Chris Molineaux welcomes guests
5:50 p.m. – Deloitte representative to say a few words
5:55 p.m. – Remarks from Karen Narolewski Engel
5:57 p.m. – Remarks from Steve Abrams
6:00 p.m. – Networking until approximately 7:00 p.m.
Karen Engel, Finance Manager- SR One
Karen joined SR One in 2002. As Finance Manager, Karen oversees SR One’s financial, legal and operational functions. In addition to expanding our relationships within the investment banking and the Mid-Atlantic investment communities, she serves as an observer on the Board of Avhana Health. Karen previously served as an observer on the Boards of Scynexis (IPO on NASDAQ, 2014), NuPathe (IPO on NASDAQ, 2010) and Rib-X Pharmaceuticals now Melinta Therapeutics.
Karen brings a range of experience to SR One, including extensive contract, legal and finance experience gained through various positions held at Quest Diagnostics, SmithKline Beecham Clinical Laboratories, and Shared Medical Systems. She received her BA from Bloomsburg University, and her MBA from LaSalle University.
SR One
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. Celebrating its 30th anniversary in 2015, SR One has invested $1B in more than 170 companies, and its current portfolio includes 40 private and public companies. Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
Steve Abrams, Partner, Hogan Lovells
As a member of the Global Life Sciences Leadership Team, Steve works with clients in many areas of the life sciences ecosystem, such as oncology therapies, pain products, dermatology therapies, vaccines, diagnostics, medical devices and drug/device combinations, orphan drugs, and gene therapies. He also counsels a variety of companies that provide services to the life sciences industry. Steve has successfully negotiated and completed a range of life sciences transactions, with a particular focus on capital market offerings (IPOs, follow-on offerings, ATMs, RDOs, PIPES, and private placements), collaboration/licensing transactions, and M&A transactions. Additionally, he regularly advises public and privately held clients, including boards of directors, on securities, governance, transactional, and a range of other complex issues.
Questions? Contact Melissa Irwin: [email protected]
*This event is for Pennsylvania Bio members only. There is no cost to attend. Space is limited; you must register in advance!
